+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Trulicity"

From
From
From
GLP-1 Agonists Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

GLP-1 Agonists Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
From
From
From
Canada Diabetes Market Report and Forecast 2025-2034 - Product Thumbnail Image

Canada Diabetes Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 250 Pages
  • Canada
From
From
From
From
From
From
From
From
Loading Indicator

Trulicity is a medication used to treat type 2 diabetes, a chronic endocrine and metabolic disorder. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to reduce blood sugar levels by stimulating the release of insulin from the pancreas. Trulicity is administered as a once-weekly subcutaneous injection and is available in both 0.75 mg and 1.5 mg doses. It is also used to reduce the risk of major cardiovascular events, such as heart attack and stroke, in adults with type 2 diabetes and established cardiovascular disease. Trulicity is part of a larger market of endocrine and metabolic disorder drugs, which includes other GLP-1 receptor agonists, such as Victoza and Bydureon, as well as insulin, sulfonylureas, and thiazolidinediones. These medications are used to treat a variety of endocrine and metabolic disorders, including diabetes, obesity, and thyroid disorders. Some companies in the Trulicity market include Eli Lilly and Company, Novo Nordisk, Merck & Co., and Sanofi. Show Less Read more